Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

VistaGen Therapeutics, Inc. (VSTA) Aims To Revive Once-Promising Drug Candidates With Latest Medicinal Technology

|Includes: VistaGen Therapeutics, Inc. (VTGN)

VistaGen is a biotech company applying human pluripotent stem cell technology for drug rescue and regenerative cell therapy. The company's drug rescue program involves combining this stem cell technology with the latest medicinal chemistry to create new chemical variants of once-promising small molecule drug candidates that were discontinued prior to market approval due to unexpected safety concerns of the heart and/or liver.

VSTA is primarily focused on leveraging its Human Clinical Trials in a Test Tube™ platform to assess heart and liver toxicity of new drug candidates in an accelerated and higher precision means versus currently used in vitro techniques and technologies. The company believes this technology to be superior as its assay systems are more applicable and accurate to human biology than currently used animal studies or other non-clinical techniques.

The company's platform is based on proprietary, exclusively licensed technologies developed by company co-founder and Canadian scientist Dr. Gordon Keller, along with VSTA co-founder, president and Chief Scientific Officer, Dr. Ralph Snodgrass.

VSTA has utilized mature heart cells produced from stem cells to develop the CardioSafe 3D bioassay system, which can predict both toxic and non-toxic in vivo cardiac effects of a drug candidate before it is ever tested on a human being. The company is also working to develop LiverSafe 3D to assess potential liver toxicity and adverse drug-drug interactions among relative drug candidates. In addition, VSTA intends to advance pilot non-clinical development of regenerative cell therapy programs focused on blood, cartilage, heart, liver, and pancreas cells.

Each of these therapy programs is based on the capabilities of the company's Human Clinical Trials in a Test Tube™ platform.

For more information, visit

Please see disclaimer on the MissionIR website